Niu Technologies

BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq:ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). Brepocitinib met the primary endpoint for both the CLARITY-1 and CLARITY-2 studies. Brepocitinib also achieved statistically significant and clinically meaningful benefit on all key secondary endpoints, including measurements of sustained steroid-free quiescence at Week 48, chorioretinal vascular leakage, resolution of macular edema and patient-reported visual functioning. These results were achieved despite a substantially more aggressive steroid taper than precedent NIU trials.

BEIJING, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today announced that it will report its financial results for the third quarter 2026 before the U.S. market opens on Monday, November 16, 2026.

BEIJING, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today provided its sales volume results for the third quarter of 2026.

The Q2 FY2026 report was a disappointment overall because while it puts NIU on track to end FY2026 with new records, earnings also got worse. The decrease in earnings are the result of several factors and there is reason to think this decrease is not something permanent. There is a silver lining to be found because NIU is still in position to improve over time, which combines well with its relatively low valuations.